Home Find a Provider Find a Provider Maxime J. Jean, M.D., Ph.D.

Maxime J. Jean, M.D., Ph.D.

He/Him/His

Specialties

Neurology

No ratings currently available, see text in Ratings section below for explanation.

URochester Medical Faculty

Accountable Health Partner

Accepting New Patients

Contact

Call Center (585) 276-3000

Maxime J. Jean, M.D., Ph.D.

View Contact & Scheduling

About Me
Credentials
Publications
Ratings & Comments

About Me

I am a board-certified neuro-oncologist and well-trained physician scientist that is currently undergoing additional training in experimental therapeutics. I seek to practice neuro-oncology in an academic setting providing culturally sensitive and compassionate care. Furthermore, I hope to help advance the field of neuro-oncology through clinical research with a focus on paraneoplastic disorders, immunotherapy applications in primary CNS tumors and neurotoxic complications from anti-neoplastic therapies (e.g. immune check point inhibitors and CAR-T cell therapies). Lastly, I am interested in developing global outreach educational and clinical programs for neuro-oncology in developing countries.

Certified Specialties

Neuro-oncology - United Council for Neurologic Subspecialties

Credentials

Residency & Fellowship

Fellowship, Clinical Researcher, University of Rochester Medical Center. 2024 - 2026

Residency, Neurology, University of Rochester Medical Center. 2020 - 2024

Education

MD | University of Rochester School of Medicine/Dentistry (USA). 2020

PhD | University of Rochester. 2018

Awards

Arnold P. Gold Foundation's Humanism in Medicine Resident Teaching Award. 2024 - 2024

Resident Clerkship Evaluation Award. 2022

Arnold P. Gold Foundation's Humanism in Medicine Resident Teaching Award. 2021

Microbiology and Immunology Department Hare award for Excellence in research.. 2019

Best departmental oral presentation by third year student in Microbiology& Immunology, University of Rochester Medical Center. 2018

Publications

Journal Articles

Management of Paraneoplastic Syndromes in the Era of Immune Checkpoint Inhibitors.

Jean MJ, Samkoff L, Mohile N

Current treatment options in oncology.. 2024 January 25 (1):42-65. Epub 01/10/2024.

GFAP astrocytopathy presenting with profound intracranial hypertension and vision loss.

Canissario R, Samkoff L, Jean MJ, Williams Z, Diep J

Journal of neuroimmunology.. 2022 December 15373 :577976. Epub 10/03/2022.

Polyamine biosynthesis and eIF5A hypusination are modulated by the DNA tumor virus KSHV and promote KSHV viral infection.

Fiches GN, Wu Z, Zhou D, Biswas A, Li TW, Kong W, Jean M, Santoso NG, Zhu J

PLoS pathogens.. 2022 April 18 (4):e1010503. Epub 04/29/2022.

Inhibition of Polo-like kinase 1 (PLK1) facilitates the elimination of HIV-1 viral reservoirs in CD4 T cells ex vivo.

Zhou D, Hayashi T, Jean M, Kong W, Fiches G, Biswas A, Liu S, Yosief HO, Zhang X, Bradner J, Qi J, Zhang W, Santoso N, Zhu J

Science advances.. 2020 July 6 (29):eaba1941. Epub 07/15/2020.

A CRISPR/Cas9 screen identifies the histone demethylase MINA53 as a novel HIV-1 latency-promoting gene (LPG).

Huang H, Kong W, Jean M, Fiches G, Zhou D, Hayashi T, Que J, Santoso N, Zhu J

Nucleic acids research.. 2019 August 2247 (14):7333-7347. Epub 1900 01 01.

Curaxin CBL0137 has the potential to reverse HIV-1 latency.

Jean MJ, Zhou D, Fiches G, Kong W, Huang H, Purmal A, Gurova K, Santoso NG, Zhu J

Journal of medical virology.. 2019 August 91 (8):1571-1576. Epub 05/01/2019.

Current Strategies for Elimination of HIV-1 Latent Reservoirs Using Chemical Compounds Targeting Host and Viral Factors.

Jean MJ, Fiches G, Hayashi T, Zhu J

AIDS research and human retroviruses.. 2019 January 35 (1):1-24. Epub 12/12/2018.

Screening of an FDA-approved compound library identifies levosimendan as a novel anti-HIV-1 agent that inhibits viral transcription.

Hayashi T, Jean M, Huang H, Simpson S, Santoso NG, Zhu J

Antiviral research.. 2017 October 146 :76-85. Epub 08/24/2017.

Identification of HIV-1 Tat-Associated Proteins Contributing to HIV-1 Transcription and Latency.

Jean MJ, Power D, Kong W, Huang H, Santoso N, Zhu J

Viruses.. 2017 April 19 (4)Epub 04/01/2017.

A Novel Bromodomain Inhibitor Reverses HIV-1 Latency through Specific Binding with BRD4 to Promote Tat and P-TEFb Association.

Huang H, Liu S, Jean M, Simpson S, Huang H, Merkley M, Hayashi T, Kong W, Rodríguez-Sánchez I, Zhang X, Yosief HO, Miao H, Que J, Kobie JJ, Bradner J, Santoso NG, Zhang W, Zhu J

Frontiers in microbiology.. 2017 8 :1035. Epub 06/07/2017.

Curaxin CBL0100 Blocks HIV-1 Replication and Reactivation through Inhibition of Viral Transcriptional Elongation.

Jean MJ, Hayashi T, Huang H, Brennan J, Simpson S, Purmal A, Gurova K, Keefer MC, Kobie JJ, Santoso NG, Zhu J

Frontiers in microbiology.. 2017 8 :2007. Epub 10/17/2017.

Adult zebrafish hearts efficiently compensate for excessive forced overload cardiac stress with hyperplastic cardiomegaly.

Jean MJ, Deverteuil P, Lopez NH, Tapia JD, Schoffstall B

BioResearch open access.. 2012 April 1 (2):88-91. Epub 1900 01 01.

Ratings & Comments

At University of Rochester Medicine, we believe that patients should be empowered to make the right decisions regarding their personal healthcare. To do so, transparency is critical. URochester Medicine partners with Press Ganey, to survey our patients about all aspects of their care experience. We are now putting this pertinent information at your fingertips by displaying star ratings for our providers along with anonymous patient comments on our website. This will help you make better-informed choices about how and with whom you seek care. Click here to learn more about the surveys used to generate this vital information. Learn more about our survey process.